Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis

Patent Citations (16)

Non-Patent Literature (50)

• Janeway et al., Immunobiology 1997, 2:19-2:21.Examiner
• Howard et al., Basic Methods in Antibody Production and Characterization. Chapter 6, 2000.Examiner
• Mackenzie et al., Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol (2013) 126:859-879.Examiner
• Mori et al., The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science vol. 339 Mar. 15, 2013, 1335-1338.Examiner
• Ash et al., Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS. Neuron 77, 639-646, Feb. 20, 2013.Examiner
• International Search Report and Written Opinion in International Application No. PCT/US2014/012801, mailed May 29, 2014, 7 pages.Applicant
• Barbas and Lerner, “Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs,” Methods: a Companion to Methods in Enzymology, 1991, 2(2):119-124.Applicant
• Boeve et al., “Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72,” Brain, 2012, 135:765-783.Applicant
• Boxer et al., “Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family,” J Neurol Neurosurg Psychiatry, 2011, 82:196-203.Applicant
• Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Nat'l. Acad. Sci. USA, 1992, 89:4285-9.Applicant
• Ciotti et al., “Triplet repeat primed PCR (TP PCR) in molecular diagnostic testing for Friedreich ataxia,” J Mol Diagn., 6(4):285-289, Nov. 2004.Applicant
• Coligan et al. Current Protocols in Immunology, 1997, sections 2.8.1, 2.8.10, 2.10.1, 2.10.4, 4 pages.Applicant
• Coligan et al., Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters, in Current Protocols in Immunology, 1992, sections 2.4.1, 2.5.1, 2.6.7, 2.7.1, 2.7.12, 2.9.1 and 2.9.3, 8 pages.Applicant
• Coligan, et al., Unit 9, Current Protocols in Immunology, Wiley Interscience, 1994, 4 pages.Applicant
• Cossée et al., “Analysis of FRDA patients with interrupted GAA expansions in the frataxin gene by fluorescent triplet primed PCR,” Eur J Hum Genet., 9(Suppl):403, 2001.Applicant
• DeJesus-Hernandez et al., “Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 causes Chromosome 9p-Linked FTD and ALS,” Neuron, 2011, 72:1-12.Applicant
• Georghiou et al., “A simple, fast, low-cost screening method for the detection of (GAA)n repeat expansions in Friedreich's ataxia,” Eur J Hum Genet., 2001, 9(Suppl 1):303.Applicant
• Giordana et al., “Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review,” Neurol. Sci., 2011, 32:9-16.Applicant
• Graff-Radford and Woodruff, “Frontotemporal dementia,” Neurol., 2007, 27:48-57.Applicant
• Green and Manson, “Production of Polyclonal Antisera,” in Immunochemical Protocols (Manson, ed.), pp. 1 5 (Humana Press 1992).Applicant
• Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,” Nature Genet., 1994, 7:13-21.Applicant
• Greene et al., “Anti-Proline-Glycine-Proline or Antielastin Autoantibodies are not Evident in Chronic Inflammatory Lung Disease,” Am J Respir Crit Case Med., 2010, 181:31-35.Applicant
• Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Pub. 1988) (Table of Contents), 10 pages.Applicant
• Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 1986, 321:522-5.Applicant
• Kobayahi et al., “Expansion of Intronic GGCCTG Hexanucleotide Repeat in NOP56 Causes SCA36, a Type of Spinocerebellar Ataxia Accompanied by Motor Neuron Involvement,” Am J Hum Gene., Jul. 2011, 89:121-130.Applicant
• Kohler & Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 1975, 256:495-7.Applicant
• Laaksovirta et al., “Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study,” Lancet Neurol., 2010, 9:978-85.Applicant
• Lomen-Hoerth et al., “Are amyotrophic lateral sclerosis patients cognitively normal?,” Neurology, 2003, 60:1094-1097.Applicant
• Lomen-Hoerth et al., “The overlap of amyotrophic lateral sclerosis and frontotemporal dementia,” Neurology, 2002, 59:1077-1079.Applicant
• Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, 1994, 368:856-9.Applicant
• Losman et al., “Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope,” Int. J. Cancer, 1990, 46:310-4.Applicant
• Mackenzie et al., “Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations,” Acta Neuropathol., 2009, 117:15-18.Applicant
• Neumann et al., “Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,” Science, 2006, 314:130-133.Applicant
• Nisonhoff et al., “Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds,” Arch. Biochem. Biophys., 1960, 89:230-44.Applicant
• Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Nat'l. Acad. Sci. USA, 1989, 86:3833-7.Applicant
• Pearson, “Repeat Associated Non-ATG Translation Initiation: One DNA, Two Transcripts, Seven Reading Frames, Potentially Nine Toxic Entities!” PLoS Genet., Mar. 2011, 7(3):e1002018, 5 pages.Applicant
• Phukan et al., “Cognitive impairment in amyotrophic lateral sclerosis,” Lancet Neurol., 2007, 6:994-1003.Applicant
• Porter, “The hydrolysis of rabbit y-globulin and antibodies with crystalline papain,” Biochem. J., 1959, 73:119-26.Applicant
• Riechmann et al., “Reshaping human antibodies for therapy,” Nature, 1988, 332:323-7.Applicant
• Rollinson et al., “Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis,” Neurobiol Aging, 2011, 21:758.e1-758.e7.Applicant
• Sandhu, “Protein engineering of antibodies,” Crit. Rev. Biotech., 1992, 12:437-62.Applicant
• Singer et al., “Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences,” J. Immunol., 1993, 150:2844-57.Applicant
• Taylor et al., “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,” Int. Immunol., 1994, 6:579-91.Applicant
• van Es et al., “Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis,” Nature Genetics, Oct. 2009, 41(10):1083-1088.Applicant
• Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science, 1988, 239:1534-6.Applicant
• Warner et al., “A general method for the detection of large CAG repeat expansions by fluorescent PCR,” J Med Genet., Dec. 1996, 33(12):1022-1026.Applicant
• Winter et al., “Making antibodies by phage display technology,” Ann. Rev. Immunol., 1994, 12:433-55.Applicant
• Zu et al., “Non-ATG—initiated translation directed by microsatellite expansions,” PNAS Jan. 2011, 108(1):260-265.Applicant
• Mann et al., “Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72,” Acta Neuropathol Commun., 1:68, Oct. 14, 2013.Applicant
• European Search Report for Application No. 14743115.9, dated Jul. 7, 2016, 10 pages.Applicant